EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pharmigene, Inc. (7595) fair value: what the stock is really worth

We calculate from audited financials what Pharmigene, Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0007595B13

PI Thin data Sep 13, 2026

Pharmigene, Inc.

7595 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 2.99 TWD · Strongly overvalued (−59%)
!Quality 24/100
!Expensive Growth (revenue 5y +14.5 %/yr)
!Loss-making · -36.5% net margin (TTM)
!High debt · negative free cash flow
!Trails peers (2/9)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Pharmigene, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

10.75 TWD 6.09 TWD Fair Value 2.99 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 13, 2026.

How to read this chart

9‑month range 6.09 TWD – 10.75 TWD · fair‑value band 2.24 TWD – 4.47 TWD · the 7.25 TWD price screens above the 2.99 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications.

Show more

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional consultation, training program, analysis software, and technical support solutions. Further, the company offers CDMO services. The company was founded in 1994 and is headquartered in Taipei, Taiwan.

Stock analysis

Pharmigene, Inc. (7595) currently trades at 7.25 TWD, while our model-based Fair Value estimate is 2.99 TWD, implying the stock looks roughly 142.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2.24 TWD (bear) to 4.47 TWD (bull), the price of 7.25 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Pharmigene, Inc. reported revenue of 200M TWD in FY2025 versus 129M TWD in FY2021, a compound +11.5%/yr. Reported net income was −73.0M TWD in FY2025.

Key figures

Market cap 366M TWD (≈ $11.5M) · P/S ratio 2.06 · EPS (TTM) −1.45 TWD · Net margin −36.5% · Return on equity −23.3% · Return on assets (EBIT) −7.3% · Operating margin −21.7% · Revenue (TTM) 200M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −59%, 7595 screens richer than that median.

Fair Value models

Bear 2.24 TWD Fair Value 2.99 TWD Bull 4.47 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2.76 TWD 3.70 TWD 5.52 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 2.76 TWD 3.70 TWD 5.52 TWD 54

Open the full fair value analysis →

Notify me when 7595 reaches fair value

Put 7595 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 24/100

Of which business quality 24 · Market factors (momentum, volatility) 27

Profitability 3
Margins and returns on capital today
Quality Growth 70
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 13
Balance sheet, leverage, solvency risk
Investment 62
Disciplined investing over empire-building
Low Volatility 53
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 15
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+71.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−13.9% (2020) → −28.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

7595 screens 142% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Pharmigene, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 140 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −59% · Bottom 25%
Profitability
Return on assets −3% · Below median
Net margin (TTM) −37% · Bottom 25%
Operating margin (TTM) −22% · Bottom 25%
Growth and dividend
Revenue growth 74% · Top 25%
Balance sheet
Debt / equity 2.04× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/S (TTM) 0.06× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 27
PAST (return on equity)0 · sector 9
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $609.82 $616.38 +1%
Danaher Corporation DHR $200.14 $207.76 +4%
WuXi AppTec Co 2359 HK$188.80 HK$213.30 +13%
Lonza Group LONN CHF 531.20 CHF 151.69 −71%
IDEXX Laboratories, Inc IDXX $504.70 $511.54 +1%
Agilent Technologies, Inc A $146.93 $61.53 −58%
Waters Corporation WAT $408.34 $103.09 −75%
IQVIA Holdings IQV $261.77 $264.34 +1%
Illumina, Inc ILMN $206.45 $227.10 +10%
Mettler-Toledo International Inc MTD $1,294 $615.78 −52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmigene, Inc. · Fair Value
2.99 TWD −142%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pharmigene, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/7595.TWO

Frequently asked questions

Is Pharmigene, Inc. (7595) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 2.99 TWD versus a price of 7.25 TWD, about −59% upside (overvalued).
What is the fair value of 7595?
Our model-based fair value for Pharmigene, Inc. is 2.99 TWD (as of Sep 13, 2026), built from audited fundamentals. The current price: 7.25 TWD.
What is the quality score of 7595?
Pharmigene, Inc. has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmigene, Inc. (7595)?
Our model-based price target is the fair value of 2.99 TWD (as of Sep 13, 2026) from 1 valuation models. Cautious scenario 2.24 TWD, optimistic scenario 4.47 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmigene, Inc. stock forecast for 2026?
Our models put fair value at 2.99 TWD, about −59% upside versus a price of 7.25 TWD (overvalued). Cautious scenario 2.24 TWD, optimistic scenario 4.47 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmigene, Inc. (7595)?
Pharmigene, Inc. reported trailing-twelve-month revenue of about 200M TWD (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Pharmigene, Inc. (7595)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmigene, Inc. it is 2.99 TWD per share (as of Sep 13, 2026), against a price of 7.25 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pharmigene, Inc. stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 7595 trades above its calculated fair value: price 7.25 TWD, fair value 2.99 TWD, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7595?
No. The price is what the market pays today (7.25 TWD); the fair value is what the company's own numbers justify (2.99 TWD). For Pharmigene, Inc. the two are 4.26 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmigene, Inc. worth?
The market values Pharmigene, Inc. at about 366M TWD (market capitalisation, as of Sep 13, 2026). Per share that is 7.25 TWD; our models calculate a fair value of 2.99 TWD per share.
What do the bullish and bearish scenarios say about 7595?
Our models span a range for Pharmigene, Inc.: cautious scenario 2.24 TWD, base 2.99 TWD, optimistic 4.47 TWD per share (as of Sep 13, 2026, price 7.25 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmigene, Inc. (7595)?
Balance-sheet figures for Pharmigene, Inc. (as of Sep 13, 2026): return on equity −23.3%, debt of 2.04 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 7595 from its 52-week high?
Pharmigene, Inc. trades at 7.25 TWD, about 39% below its 52-week high of 11.85 TWD and 4% above the low of 7.00 TWD (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 2.99 TWD is for.
Which stocks are comparable to Pharmigene, Inc.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmigene, Inc. stock attractive at the current price?
The data as of Sep 13, 2026: price 7.25 TWD, calculated fair value 2.99 TWD (−59%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7595 calculated?
We run Pharmigene, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.99 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Pharmigene, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Pharmigene, Inc. right now?
The price sits above even our optimistic bull case (4.47 TWD). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.24 TWD to 4.47 TWD) leaves room in how you read the outcome.

Key figures of Pharmigene, Inc.

How large is the market capitalisation of Pharmigene, Inc. (7595)?
The market capitalisation of Pharmigene, Inc. is 366M TWD (≈ $11.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmigene, Inc. (7595)?
The price-to-sales ratio of Pharmigene, Inc. is 2.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmigene, Inc. (7595)?
Earnings per share at Pharmigene, Inc. are −1.45 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pharmigene, Inc. (7595)?
The net margin of Pharmigene, Inc. is −36.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmigene, Inc. (7595)?
The return on equity (ROE) of Pharmigene, Inc. is −23.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmigene, Inc. (7595)?
On an EBIT basis the return on assets of Pharmigene, Inc. is −7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmigene, Inc. (7595)?
The operating margin of Pharmigene, Inc. is −21.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmigene, Inc. (7595)?
Revenue at Pharmigene, Inc. is growing +73.8% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmigene, Inc. (7595) generate?
The free cash flow of Pharmigene, Inc. is −76.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmigene, Inc. (7595) carry?
The net debt of Pharmigene, Inc. is 595M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pharmigene, Inc. in the live analysis

One click puts Pharmigene, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.